Prtn3-flox Mouse
一般名
Prtn3-flox
製品ID
S-CKO-18393
背景情報
C57BL/6JCya
系統ID
CKOCMP-19152-Prtn3-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Prtn3-flox Mouse(カタログ番号S-CKO-18393)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Prtn3-flox
系統ID
CKOCMP-19152-Prtn3-B6J-VB
遺伝子名
製品ID
S-CKO-18393
遺伝子別名
PR3, PR-3, mPR3
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 10
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000006679
NCBIトランスクリプトID
NM_011178
ターゲット領域
Exon 2
有効領域の大きさ
~0.6 kb
遺伝子研究の概要
Prtn3, also known as proteinase 3, is a protein-encoding gene. Proteinase 3 is a serine protease that has been implicated in various biological processes and diseases. It is involved in immune-inflammatory responses, cancer-related pathways such as the PI3K/AKT and P38/ERK signaling pathways, and may play a role in collagen degradation in the tumor microenvironment [1,2,7].
In a myeloid cells-specific Prtn3-knockout mouse model, Prtn3 deficiency in macrophages was shown to remold the immunosuppressive tumor microenvironment and suppress tumor growth in lung adenocarcinoma. This indicated that Prtn3 in macrophages acts as a key immunoregulator, enhancing IL33/Treg-mediated tumor immunosuppression by promoting M2 polarization of tumor-associated macrophages [2]. In another study, genetic elimination of Prtn3 in mice led to spontaneous myeloid differentiation. Mechanistically, Prtn3 was found to interact with the N-terminal of STAT3, promoting STAT3 ubiquitination and degradation, thus negatively regulating STAT3-dependent myeloid differentiation. Deficiency of Prtn3 in primary AML blasts promoted their differentiation into functional neutrophils, improving overall survival rates for recipients [5].
In conclusion, Prtn3 plays crucial roles in tumor-related immunosuppression and myeloid differentiation. Studies using Prtn3 knockout mouse models have provided valuable insights into its functions in lung adenocarcinoma and leukemia, highlighting its potential as a therapeutic target in these disease areas. Additionally, Prtn3 may be involved in other cancer-related processes and could potentially serve as a biomarker in diseases like early gastric cancer, esophageal cancer, and pancreatic cancer, as well as in sepsis diagnosis and periprosthetic joint infection [1,2,3,4,6,7,8].
References:
1. Shi, Zheng-Rong, Duan, Yu-Xin, Cui, Fang, Tang, Wei, Liao, Rui. 2023. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation. In Journal of experimental & clinical cancer research : CR, 42, 133. doi:10.1186/s13046-023-02716-y. https://pubmed.ncbi.nlm.nih.gov/37231509/
2. Jiang, Jiayu, Chen, Huilin, Zhao, Chunxing, Chen, Chong, Luo, Yunping. 2025. PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma. In Cancer letters, 616, 217584. doi:10.1016/j.canlet.2025.217584. https://pubmed.ncbi.nlm.nih.gov/39993649/
3. Guo, Daxin, Zhang, Biying, Wu, Dong, Hu, Xujun, Tu, Hanxiao. 2023. Identification of PRTN3 as a novel biomarker for the diagnosis of early gastric cance. In Journal of proteomics, 277, 104852. doi:10.1016/j.jprot.2023.104852. https://pubmed.ncbi.nlm.nih.gov/36804624/
4. Lei, Jing, Xu, Feng, Deng, Chao, He, Song, Chen, Yongyu. 2023. Fusobacterium nucleatum promotes the early occurrence of esophageal cancer through upregulation of IL-32/PRTN3 expression. In Cancer science, 114, 2414-2428. doi:10.1111/cas.15787. https://pubmed.ncbi.nlm.nih.gov/36919771/
5. Liu, Huan, Sun, Lu, Zhao, Hongfei, Cao, Yihai, Xu, Yuanfu. 2024. Proteinase 3 depletion attenuates leukemia by promoting myeloid differentiation. In Cell death and differentiation, 31, 697-710. doi:10.1038/s41418-024-01288-4. https://pubmed.ncbi.nlm.nih.gov/38589495/
6. Zhang, Wenyuan. 2024. Critical roles of S100A12, MMP9, and PRTN3 in sepsis diagnosis: Insights from multiple microarray data analyses. In Computers in biology and medicine, 171, 108222. doi:10.1016/j.compbiomed.2024.108222. https://pubmed.ncbi.nlm.nih.gov/38447501/
7. Hu, Dingyuan, Ansari, Daniel, Zhou, Qimin, Said Hilmersson, Katarzyna, Andersson, Roland. 2019. Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer. In Scandinavian journal of gastroenterology, 54, 246-251. doi:10.1080/00365521.2019.1574360. https://pubmed.ncbi.nlm.nih.gov/30880498/
8. Wang, Chi, Wang, Qi, Li, Rui, Chen, Jiying, Wang, Chengbin. . LTF, PRTN3, and MNDA in Synovial Fluid as Promising Biomarkers for Periprosthetic Joint Infection: Identification by Quadrupole Orbital-Trap Mass Spectrometry. In The Journal of bone and joint surgery. American volume, 101, 2226-2234. doi:10.2106/JBJS.18.01483. https://pubmed.ncbi.nlm.nih.gov/31644522/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
